Literature DB >> 3874608

Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis?

O S Als, A Gotfredsen, B J Riis, C Christiansen.   

Abstract

One hundred and five patients with rheumatoid arthritis treated with a variety of antirheumatic drugs, excepting glucocorticoids, were stratified according to the degree of functional impairment (functional classes I to IV) and duration of the disease (0-3 years; 4-8 years; and greater than 8 years). The variables investigated were distal forearm bone mineral content (BMC), biochemical markers of bone formation: serum alkaline phosphatase and serum bone gamma-carboxyglutamic acid containing protein (BGP) and biochemical markers of bone resorption: fasting urinary calcium and fasting urinary hydroxyproline. Significant relationships were found between BMC and functional impairment and duration of the disease. Indices of bone formation and bone resorption rose with increasing functional impairment, particularly those of bone resorption. It is concluded that disability induces osteopenia in rheumatoid arthritis by increasing the bone turnover with a more marked increased in resorption than in the formation processes. The effect of the disease duration is merely that of adding more years of functional impairment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874608      PMCID: PMC1001661          DOI: 10.1136/ard.44.6.406

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Bone mineral density in rheumatoid arthritis measured by the gamma transmission method.

Authors:  M Oka; A Rekonen; J Kuikka; J Anttinen
Journal:  Scand J Rheumatol       Date:  1975       Impact factor: 3.641

2.  Bone mineral content in the forearm measured by photon absorptiometry. Principles and reliability.

Authors:  C Christiansen; P Rödbro; H Jensen
Journal:  Scand J Clin Lab Invest       Date:  1975-07       Impact factor: 1.713

3.  Proceedings: Bone mineral determinations on long-term diabetics.

Authors:  J D Ringe; F Kuhlencordt; H P Kruse
Journal:  AJR Am J Roentgenol       Date:  1976-06       Impact factor: 3.959

4.  Bone loss in patients with rheumatoid arthritis.

Authors:  A C Kennedy; D A Smith; W W Buchanan; J B Anderson; M K Jasani
Journal:  Scand J Rheumatol       Date:  1975       Impact factor: 3.641

Review 5.  Diagnostic procedures in disorders of calcium metabolism.

Authors:  B E Nordin
Journal:  Clin Endocrinol (Oxf)       Date:  1978-01       Impact factor: 3.478

6.  Osteoporosis in rheumatoid arthritis. A follow-up study.

Authors:  P Virtama; T Helelä; J L Kalliomäki
Journal:  Acta Rheumatol Scand       Date:  1968

7.  Serum biochemical values in rheumatoid disease.

Authors:  R Cockel; M J Kendall; J F Becker; C F Hawkins
Journal:  Ann Rheum Dis       Date:  1971-03       Impact factor: 19.103

8.  Liver disease in rheumatoid arthritis and Sjøgren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction.

Authors:  J Webb; K Whaley; R N MacSween; G Nuki; W C Dick; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1975-02       Impact factor: 19.103

9.  Osteoporosis of rheumatoid arthritis: influence of age, sex and corticosteroids.

Authors:  P D Saville; O Kharmosh
Journal:  Arthritis Rheum       Date:  1967-10

10.  Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease.

Authors:  T Lauffenburger; A J Olah; M A Dambacher; J Guncaga; C Lentner; H G Haas
Journal:  Metabolism       Date:  1977-06       Impact factor: 8.694

View more
  30 in total

Review 1.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

Review 2.  Bone mass in patients with rheumatoid arthritis.

Authors:  R F Laan; P L van Riel; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

3.  Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Authors:  Mona Helmy Abdel Meguid; Yousry Hasan Hamad; Rania Shafek Swilam; Mohamed Samy Barakat
Journal:  Rheumatol Int       Date:  2012-04-25       Impact factor: 2.631

Review 4.  Bone metabolism in patients with rheumatoid arthritis.

Authors:  J W Bijlsma
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

5.  Clinical assessment of disease activity in rheumatoid arthritis: evaluation of a functional test.

Authors:  A A Kalla; T J Kotze; O L Meyers; N D Parkyn
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

6.  Serum concentration of vitamin D metabolites in rheumatoid arthritis.

Authors:  O S Als; B Riis; C Christiansen
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

7.  Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.

Authors:  A J Taggart; C Astbury; J S Dixon; H A Bird
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

8.  Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis.

Authors:  M Güler-Yüksel; J Bijsterbosch; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; H K Ronday; A J Peeters; J M de Jonge-Bok; F C Breedveld; B A C Dijkmans; C F Allaart; W F Lems
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

9.  Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study.

Authors:  H Rico; E R Hernandez; F Gomez-Castresana; M Yague; J A Cabranes; R Valor
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

10.  Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis.

Authors:  A A Deodhar; J Brabyn; P W Jones; M J Davis; A D Woolf
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.